 |
市場調査レポート
商品コード
1174974
帯状疱疹治療の世界市場：市場規模 - 投与経路別、治療タイプ別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年）Herpes Zoster Treatment Market Size- By Route Of Administration, By Treatment Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032 |
||||||
価格
| 帯状疱疹治療の世界市場：市場規模 - 投与経路別、治療タイプ別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年） |
|
出版日: 2022年12月05日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 238 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 目次
概要
世界の帯状疱疹治療の市場規模は、2032年までに3億2,000万米ドルに達し、CAGRで3.68%の成長が予測されています。
COVID-19の影響により、病院や医療機関では非選択的な処置が延期されましたが、帯状疱疹治療市場は徐々に回復していくと予想されます。
当レポートでは、世界の帯状疱疹治療市場について調査し、市場力学、市場変数と展望、投与経路・治療タイプ・流通チャネル・地域別の市場分析、企業プロファイル等に関する情報を提供しています。
目次
第1章 イントロダクション
- 調査範囲
- 市場セグメント分析
第2章 調査手法
- 調査データソース
- 市場規模の推定
- データの三角測量
第3章 エグゼクティブサマリー
第4章 市場力学
- 促進要因、抑制要因、機会、課題の分析
- 促進要因
- 抑制要因
- 機会
- 課題
- 世界の帯状疱疹治療市場におけるCOVID-19の影響
第5章 市場変数と展望
- SWOT分析
- 強み
- 弱み
- 機会
- 脅威
- PESTEL分析
- 政治情勢
- 経済情勢
- 社会情勢
- 技術情勢
- 環境情勢
- 法的情勢
- ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入者の脅威
- 競合企業間の敵対関係
- ヒートマップ分析
第6章 世界の帯状疱疹治療市場：投与経路別（2019年～2032年（100万米ドル））
- 経口
- 局所
第7章 世界の帯状疱疹治療市場：治療タイプ別（2019年～2032年（100万米ドル））
- 抗ウイルス剤
- 抗炎症剤
- その他
第8章 世界の帯状疱疹治療市場：流通チャネル別（2019年～2032年（100万米ドル））
- ドラッグストア・小売薬局
- 病院薬局
- オンラインプロバイダー
第9章 世界の帯状疱疹治療市場：地域別（2019年～2032年（100万米ドル））
- 北米
- 米国
- カナダ
- メキシコ
- 欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他の欧州
- アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋
- 南米
- ブラジル
- アルゼンチン
- その他の南米
- 中東・アフリカ
- サウジアラビア王国
- アラブ首長国連邦
- その他の中東・アフリカ
第10章 企業プロファイル
- Abbott Laboratory
- 企業概要
- 財務展望
- 製品概要
- 最近の開発
- Bausch Health
- Camber Pharmaceuticals
- Cipla Inc.
- Eli Lilly and Co.
- GlaxoSmithKline PLC
- Merck
- Novaritis AG
- GoodRx
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
目次
Product Code: HLCA2221
Global Herpes Zoster Treatment Market Overview:
According to SPER Market Research, the Global Herpes Zoster Treatment Market is estimated to reach USD 0.32 billion by 2032 with a CAGR of 3.68%.
The varicella-zoster virus is the cause of the viral illness known as herpes zoster (shingles). It often starts as a burning, itchy skin rash that spreads to the rest of the body, causing blisters on the back, chest, and face. Pain along the afflicted dermatome is usually the first symptom, which is followed in 2-3 days by an expanded vesicular eruption. Lymph nodes, fever, chills, and headache are among the symptoms. There may also be itching, raised spots on the skin, localised redness, a stabbing or shooting pain, tingling or burning sensation in or beneath the skin, or an upset stomach.
Impact of COVID-19 on the Global Herpes Zoster Treatment Market
In order to prevent cross-contamination, fewer procedures and patients have visited hospitals. This has a detrimental effect on the market for herpes zoster medications. Additionally, a reduction in staff was made to care for patients receiving herpes zoster therapy as a result of the transfer in medical personnel to treat COVID-19-infected individuals. As a result, non-elective procedures were delayed at several hospitals and healthcare institutes. The market for herpes zoster medications, however, is anticipated to gradually rebound after the epidemic.
Scope of the Report:
- Market size available for years: 2019-2032
- Base year considered: 2021
- Forecast period: 2022-2032
- Segments covered: By Route Of Administration, By Treatment Type, By Distribution Channel
- Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
- Companies Covered: Abbott Laboratory, Bausch Health, Camber Pharmaceuticals, Cipla Inc., Eli Lilly and Co., GlaxoSmithKline PLC, Merck, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Global Herpes Zoster Treatment Market Segmentation:
- By Route Of Administration: Based on the Route Of Administration, Global Herpes Zoster Treatment Market is segmented as; Oral and Topical.
- By Treatment Type: Based on the Treatment Type, Global Herpes Zoster Treatment Market is segmented as; Antiviral Medications, Anti-inflammatory Medications and Other.
- By Distribution Channel: Based on the Distribution Channel, Global Herpes Zoster Treatment Market is segmented as; Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Provider.
- By Region: In terms of revenue, North America led the world market for treating herpes zoster and is predicted to maintain that position. This is a result of the presence of important actors throughout the region and the accessibility of cutting-edge healthcare facilities with skilled medical personnel.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Global Herpes Zoster Treatment Market
5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4. Heat map analysis
6. Global Herpes Zoster Treatment Market, By Route Of Administration, 2019-2032 (USD Million)
- 6.1. Oral
- 6.2. Topical
7. Global Herpes Zoster Treatment Market, By Treatment Type, 2019-2032 (USD Million)
- 7.1. Antiviral Medication
- 7.2. Anti-inflammatory Medications
- 7.3. other
8. Global Herpes Zoster Treatment Market, By Distribution Channel, 2019-2032 (USD Million)
- 8.1. Drug Stores & Retail Pharmacies
- 8.2. Hospital Pharmacies
- 8.3. Online Provider
9. Global Herpes Zoster Treatment Market, By Region, 2019-2032 (USD Million)
- 9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
- 9.2 Europe
- 9.2.1 Germany
- 9.2.2 United Kingdom
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Rest of Europe
- 9.3 Asia-Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
- 9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Rest of South America
- 9.5 Middle East & Africa
- 9.5.1 Kingdom of Saudi Arabia
- 9.5.2 United Arab Emirates
- 9.5.3 Rest of Middle East & Africa
10. Company Profiles
- 10.1 Abbott Laboratory
- 10.1.1 Company details
- 10.1.2 Financial outlook
- 10.1.3 Product summary
- 10.1.4 Recent developments
- 10.2 Bausch Health
- 10.2.1 Company details
- 10.2.2 Financial outlook
- 10.2.3 Product summary
- 10.2.4 Recent developments
- 10.3 Camber Pharmaceuticals
- 10.3.1 Company details
- 10.3.2 Financial outlook
- 10.3.3 Product summary
- 10.3.4 Recent developments
- 10.4 Cipla Inc.
- 10.4.1 Company details
- 10.4.2 Financial outlook
- 10.4.3 Product summary
- 10.4.4 Recent developments
- 10.5 Eli Lilly and Co.
- 10.5.1 Company details
- 10.5.2 Financial outlook
- 10.5.3 Product summary
- 10.5.4 Recent developments
- 10.6 GlaxoSmithKline PLC
- 10.6.1 Company details
- 10.6.2 Financial outlook
- 10.6.3 Product summary
- 10.6.4 Recent developments
- 10.7 Merck
- 10.7.1 Company details
- 10.7.2 Financial outlook
- 10.7.3 Product summary
- 10.7.4 Recent developments
- 10.8 Novaritis AG
- 10.8.1 Company details
- 10.8.2 Financial outlook
- 10.8.3 Product summary
- 10.8.4 Recent developments
- 10.9 GoodRx
- 10.9.1 Company details
- 10.9.2 Financial outlook
- 10.9.3 Product summary
- 10.9.4 Recent developments
- 10.10 Pfizer Inc.
- 10.10.1 Company details
- 10.10.2 Financial outlook
- 10.10.3 Product summary
- 10.10.4 Recent developments
- 10.11 Teva Pharmaceutical Industries Ltd.
- 10.11.1 Company details
- 10.11.2 Financial outlook
- 10.11.3 Product summary
- 10.11.4 Recent developments
